Comparative Pharmacology
Head-to-head clinical analysis: PLETAL versus PYRIDAMAL 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLETAL versus PYRIDAMAL 100.
PLETAL vs PYRIDAMAL 100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
Dipyridamole inhibits platelet phosphodiesterase, reducing platelet aggregation; also inhibits adenosine deaminase and increases extracellular adenosine, leading to vasodilation.
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
100 mg orally three times daily.
None Documented
None Documented
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Terminal half-life 10-12 hours; clinical context: steady state achieved in 3-5 days; renal impairment prolongs half-life
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Renal: 50-70% unchanged; biliary/fecal: 20-30% as metabolites; total renal elimination ~85%
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent